AIM ImmunoTech (AIM) Convertible Debt (2018 - 2019)
AIM ImmunoTech's (AIM) quarterly Convertible Debt came in at $2.3 million in Q3 2019, down 32.48% YoY from $3.4 million in Q3 2018, and little changed on a QoQ basis from $2.3 million in Q2 2019.
AIM ImmunoTech (AIM) Convertible Debt (2018 - 2019) Analysis & Trends
AIM ImmunoTech (AIM) has 2 years of Convertible Debt data on file, last reported at $2.3 million in Q3 2019.
- Quarterly Convertible Debt fell 32.48% year-over-year to $2.3 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $2.3 million (down 32.48% YoY) and the FY2018 annual result came in at $3.4 million, changed N/A from the prior year.
- Convertible Debt held at $2.3 million in Q3 2019, from $2.3 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $3.7 million in Q1 2019 to a low of $2.3 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | AIM ImmunoTech | 4.42 Mn | -5.54 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 2.29 Mn |
| Jun 30, 2019 | 2.28 Mn |
| Mar 31, 2019 | 3.68 Mn |
| Dec 31, 2018 | 3.41 Mn |
| Sep 30, 2018 | 3.39 Mn |